前沿速览023期| CAR-T治B淋 前沿览新知
01
CD5缺失可增强过继性T细胞疗法的抗肿瘤活性
CD5 deletion enhances the antitumor activity of adoptive T cell therapies
第一作者：Patel RP
Sci Immunol (IF=17.6). 2024 Jul 19;9(97):eadn6509.
全文网址：https://www.science.org/doi/10.1126/sciimmunol.adn6509?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
02
随着时间的推移，接受CAR-T治疗患者的COVID-19感染结局有所改善：EBMT传染病工作组和EHA淋巴瘤小组进行的欧洲COVID-19多中心研究的最新进展
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group
第一作者：Spanjaart AM
Leukemia (IF=12.8). 2024 Jul 23.
全文网址：https://www.nature.com/articles/s41375-024-02336-1
03
细胞治疗和双特异性抗体治疗弥漫性大B细胞淋巴瘤的排序分析
Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma
第一作者：Melody M
Haematologica (IF=8.2). 2024 Jul 18.
全文网址：https://haematologica.org/article/view/haematol.2024.285255
04
一种新型非串联嵌合抗原受体，重定向以靶向CD20-CD19双阳性B细胞急性白血病和B细胞淋巴瘤
A nontandem novel compound chimeric antigen receptor redirected to target CD20-CD19 positive B-cell acute leukemias and B-cell lymphoma
第一作者：DeStefano VM
Clin Transl Med (IF=7.9). 2024 Jul;14(7):e1743.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11263732/
05
儿科血液肿瘤患者匹配治疗的致癌和免疫学靶点：荷兰iTHER研究经验
Oncogenic and immunological targets for matched therapy of pediatric blood cancer patients: Dutch iTHER study experience
第一作者：Boer JM
Hemasphere (IF=7.6). 2024 Jul 15;8(7):e122.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11247331/
06
T细胞的参与规则：CAR-T细胞和双特异性抗体治疗B细胞淋巴瘤的现状
The Rules of T-cell Engagement: Current State of CAR T-cells and Bispecific Antibodies in B-cell Lymphomas
第一作者：Haydu JE
Blood Adv（IF=7.4）. 2024 Jul 23:bloodadvances.2021004535.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2021004535/517129/The-Rules-of-T-cell-Engagement-Current-State-of
07
优化Axicabtagene Ciloleucel、Tisagenlecleucel和Lisocabtagene Maraleucel三种CAR-T细胞产品回输后的监测期管理
Optimizing the Post-CAR T Monitoring Period for Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel
第一作者：Ahmed N
Blood Adv (IF=7.4). 2024 Jul 23:bloodadvances.2023012549.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2023012549/517124/Optimizing-the-Post-CAR-T-Monitoring-Period-for
08
CAR-T治疗前伴或不伴放疗桥接的局限期（<5个病灶）r/r B-NHL患者后的疗效比较
Outcomes of r/r B-cell NHL patients with limited (<5 Sites) pre-CART Disease Bridged With or Without Radiotherapy
第一作者：Saifi O
Blood Adv (IF=7.4). 2024 Jul 19:bloodadvances.2024013647.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024013647/517115/Outcomes-of-r-r-B-cell-NHL-patients-with-limited
09
个性化CAR-T疗法的进展：血液恶性肿瘤的生物标记物和治疗靶点综述
Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies
第一作者：Olejarz W
Int J Mol Sci (IF=4.9). 2024 Jul 15;25(14):7743.
全文网址：https://www.mdpi.com/1422-0067/25/14/7743
10
CD19 CAR-T细胞治疗老年患者：来自GETH-TC/GELTAMO的多中心真实世界经验
Anti-CD19 CAR-T cell therapy in elderly patients: multicentric real-world experience from GETH-TC/GELTAMO
第一作者：Bailén R
Transplant Cell Ther (IF=3.6). 2024 Jul 26:S2666-6367(24)00485-8.
全文网址：https://linkinghub.elsevier.com/retrieve/pii/S2666-6367(24)00485-8
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2024.8-1 valid until 2026.8
供稿与审核：临床开发与医学部